Comparative epidemiology of bacteremia due to methicillin- resistant staphylococcus aureus between older and younger adults: A propensity score analysis

Infection Control and Hospital Epidemiology

Volumn 34, Issue 4, 2013, Pages 400-406

  Kullar, Ravina ^a   Rybak, Michael J ^b   Kaye, Keith S ^b  

^a OREGON STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; AGE; AGED; APACHE; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CATHETER INFECTION; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; DRUG DOSE COMPARISON; ENDOCARDITIS; EPSILOMETER TEST; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICHIGAN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84874889005     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/669868     Document Type: Article

References (36)

1. Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012-3021.
2. Hill EE, Herijgers P, Herregods MC, et al. Evolving trends in infective endocarditis. Clin Microbiol Infect 2006;12:5-12.
3. National Nosocomial Infections Surveillance (NNIS) System Report, Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
4. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598.
5. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-59.
6. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005;52:113-122.
7. McClelland RS, Fowler VG Jr, Sanders LL, et al. Staphylococcus aureus bacteremia among elderly vs younger adult patients: comparison of clinical features and mortality. Arch Intern Med 1999; 159:1244-1247.
8. Lee CC, Chen SY, Chang IJ, et al. Comparison of clinical manifestations and outcome of community-acquired bloodstream infections among the oldest old, elderly, and adult patients. Medicine 2007;86:138-144.
9. Bradley SF. Staphylococcus aureus infections and antibiotic resistance in older adults. Clin Infect Dis 2002;34:211-216.
10. Bader MS. Staphylococcus aureus bacteremia in older adults: predictors of 7-day mortality and infection with a methicillinresistant strain. Infect Control Hosp Epidemiol 2006;27:1219-1225.
11. Kaye KS, Marchaim D, Chen TY, et al. Predictors of nosocomial bloodstream infections in older adults. J Am Geriatr Soc 2011; 59:622-627.
12. Forsblom E, Ruotsalainen E, Molkanen T, et al. Predisposing factors, disease progression and outcome in 430 prospectively followed patients of healthcare- and community-associated Staphylococcus aureus bacteraemia. J Hosp Infect 2011;78:102-107.
13. Nolan CM, Beaty HN. Staphylococcus aureus bacteremia: current clinical patterns. Am J Med 1976;60:495-500.
14. Levine DP. Vancomycin: understanding its past and preserving its future. South Med J 2008;101:284-291.
15. Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guide- lines suggested targets. Clin Infect Dis 2011;52:975-981.
16. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-2402.
17. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42(suppl 1):S35-S39.
18. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/ static activity, and applied breakpoints to predict clinical out- comes or detect resistant strains. Clin Infect Dis 2006;42(suppl 1):S13-S24.
19. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007;45(suppl 3):S191-S195.
20. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
21. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006;38:7-14.
22. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52:1330-1336.
23. Fowler VG Jr, Sakoulas G, McIntyre LM, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004;190:1140-1149.
24. Hawkins C, Huang J, Jin N, et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007;167:1861-1867.
25. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-680.
26. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-140.
27. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically; Approved Standard. 8th ed. Wayne, PA: CLSI, 2009. CLSI document M7-A8.
28. Rybak MJ, Leonard SN, Rossi KL, et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008;46:2950-2954.
29. Wootton M, MacGowan AP, Walsh TR, et al. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007;45:329-332.
30. Zhang K, McClure JA, Elsayed S, et al. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillinresistant Staphylococcus aureus. J Clin Microbiol 2005;43:5026-5033.
31. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128-1132.
32. Freeborne N, Lynn J, Desbiens NA. Insights about dying from the SUPPORT project: the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. J Am Geriatr Soc 2000;48:S199-S205.
33. Levinsky NG, Yu W, Ash A, et al. Influence of age on Medicare expenditures and medical care in the last year of life. JAMA 2001;286:1349-1355.
34. Hiramatsu K, Cui L, Kuroda M, et al. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001;9:486-493.
35. Herold BC, Immergluck LC, Maranan MC, et al. Community- acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-598.
36. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-2984.